Topical fulvestrant solution has no effect on male and postmenopausal female androgenetic alopecia: results from two randomized, proof-of-concept studies

Gassmueller, J.; Hoffmann, Rolf; Webster, Alan

doi:10.1111/j.1365-2133.2007.08276.x

Cited by 16 publications

(23 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…4,34 In contrast to previous findings, no pattern or patchy alopecia was found in this study. 14 There is little evidence in the current literature that oestrogens affect human hair growth one way or the other, 36 possibly indicating a role of genetic predisposition in oestrogen-related hair changes. However, interestingly a mild and temporary decrease in anagen hairs and hair density was found in the frontal region.…”

Section: Discussionmentioning

confidence: 99%

Analysis of quantitative changes in hair growth during treatment with chemotherapy or tamoxifen in patients with breast cancer: a cohort study

et al. 2014

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Analysis of quantitative changes in hair growth during treatment with chemotherapy or tamoxifen in patients with breast cancer: a cohort study

et al. 2014

View full text Add to dashboard Cite

show abstract

“…A recent study of topical estrogen (fulvestrant) documented increased hair growth in a murine model, but failed to show improvement in men and women with pattern baldness 109. Contrastingly, topical 17α-estradiol demonstrated increased hair counts and diameter after 8 months of use in a Phase IV open-label trial in Korean women 25.…”

Section: Treatmentmentioning

confidence: 96%

Female pattern alopecia: current perspectives

Levy¹,

Emer²

2013

IJWH

View full text Add to dashboard Cite

Hair loss is a commonly encountered problem in clinical practice, with men presenting with a distinctive pattern involving hairline recession and vertex balding (Norwood-Hamilton classification) and women exhibiting diffuse hair thinning over the crown (increased part width) and sparing of the frontal hairline (Ludwig classification). Female pattern hair loss has a strikingly overwhelming psychological effect; thus, successful treatments are necessary. Difficulty lies in successful treatment interventions, as only two medications – minoxidil and finasteride – are approved for the treatment of androgenetic alopecia, and these medications offer mediocre results, lack of a permanent cure, and potential complications. Hair transplantation is the only current successful permanent option, and it requires surgical procedures. Several other medical options, such as antiandrogens (eg, spironolactone, oral contraceptives, cyproterone, flutamide, dutasteride), prostaglandin analogs (eg, bimatoprost, latanoprost), and ketoconazole are reported to be beneficial. Laser and light therapies have also become popular despite the lack of a profound benefit. Management of expectations is crucial, and the aim of therapy, given the current therapeutic options, is to slow or stop disease progression with contentment despite patient expectations of permanent hair regrowth. This article reviews current perspectives on therapeutic options for female pattern hair loss.

show abstract

“…Finasteride (Propecia) is a potent 5α-reductase inhibitor and is expected to stop the progression of AGA, both by gel and by tablet similarly. [4] The effectiveness of minoxidil,[5] Serenoa repens (especially for AGA of the vertex[6]) and a combination of medical treatment with hair transplant surgery have also been reported. [7]…”

Section: Introductionmentioning

confidence: 99%

Efficacy of finasteride for treating patients with androgenetic alopecia who are pileous in other areas: A pilot study in Japan

Inadomi¹

2014

Indian J Dermatol

View full text Add to dashboard Cite

Background:Androgenetic alopecia (AGA) involves androgen-dependent hair loss and finasteride is an established treatment for the disease. However, reports of the influence of finasteride on hair growth in other areas of the body are lacking.Aims:To investigate the effects of finasteride on hair, including the head and other areas of the body.Materials and Methods:Based on whether AGA patients felt they were pileous in areas other than the head, they were divided into Group A (pileous) or Group B (not pileous). Finasteride (1 mg/day) was prescribed for both groups for at least 6 months, after which patients were asked to estimate the medicine's effects and any changes of their hair growth.Results and Conclusions:A total of 18 out of 37 patients were placed in Group A and 19 of them were in Group B, suggesting that about half of AGA patients in Japan are pileous in other parts of the body. Oral finasteride was effective (excellent or good) in 22 out of 37 (59.5%) patients overall, in 16 out of 18 (88.9%) patients in Group A, and in 6 out of 19 (31.6%) patients in Group B. None of the patients reported that oral finasteride had any effect on their hair growth other than on their head. Finasteride is more effective for treating AGA patients who are pileous in other areas of the body.

show abstract

Topical fulvestrant solution has no effect on male and postmenopausal female androgenetic alopecia: results from two randomized, proof-of-concept studies

Abstract: These results indicate a lack of effect of topical fulvestrant in the treatment of subjects with androgenetic alopecia. The reasons for this lack of effect remain unclear.

Cited by 16 publications

References 27 publications

Analysis of quantitative changes in hair growth during treatment with chemotherapy or tamoxifen in patients with breast cancer: a cohort study

Analysis of quantitative changes in hair growth during treatment with chemotherapy or tamoxifen in patients with breast cancer: a cohort study

Female pattern alopecia: current perspectives

Efficacy of finasteride for treating patients with androgenetic alopecia who are pileous in other areas: A pilot study in Japan

Contact Info

Product

Resources

About